Novel Drug Effective Against MASH in Phase II Trial
Fatty acid synthase inhibitor targets main drivers of liver injury
Related Articles
Alzheimer’s Slowed by Intensive Lifestyle Changes
Small trial led by Dean Ornish, MD, shows cognitive improvement
Third-Generation PCSK9 Inhibitor Cuts Cholesterol With Single, Small, Monthly Shot
Patient acceptance could be an advantage, researchers say
Elevating Family Medicine Is Key for New AAFP President
Jen Brull, MD, outlines her priorities for the coming year
Over 400 Physicians From Delaware’s ChristianaCare Move to Unionize
‘This is a movement that needs to happen in medicine,’ one physician said
FDA Panel Mulls Which Devices Are Critical in a Public Health Emergency
‘If we have a thermonuclear war, all I need is a scalpel,’ one panel member said
Elon Musk’s Ketamine Use
Musk says his prescription for the drug helps him get out of a ‘depressive mind state’
PTSD Ran High Among Physicians During COVID-19 Pandemic
Female physicians, trainees more likely to develop the condition
Public Health Experts Concerned About Rise in Measles Cases
New cases across states put U.S. on pace to surpass last year’s count
Journal of Clinical Gastroenterology
Journal of Clinical Gastroenterology gathers the world’s latest, most relevant clinical studies and reviews, case reports, and technical expertise in a single source. Regular features…
Effects of Intermittent Calorie Restriction in Nondiabetic Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease
We compared the effects of a 12-week intermittent calorie restriction (ICR) and standard-of-care (SOC) diet on liver fat content (LFC) in metabolic dysfunction–associated steatotic liver…
